Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.45 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129623 | 0.94 | PTGER1 (0.75) | PTGER1LMNAKDM4ETBXA2RALDH1A1 | |
| SCHEMBL4724734 | 0.90 | PTGER1 (0.84) | PTGER1CYP2C9KDM4ETBXA2RALDH1A1 | |
| SCHEMBL5125104 | 0.89 | PTGER1 (0.66) | PTGER1LMNAKDM4ESMN1; SMN2TBXA2R | |
| SCHEMBL14098697 | 0.87 | PTGER1 (0.61) | PTGER1LMNACYP2C9KDM4ESMN1; SMN2 | |
| SCHEMBL5130647 | 0.87 | PTGER1 (0.58) | PTGER1LMNACYP2C9KDM4ESMN1; SMN2 | |
| SCHEMBL5123623 | 0.87 | PTGER1 (0.58) | PTGER1LMNACYP2C9KDM4ESMN1; SMN2 | |
| SCHEMBL5129850 | 0.87 | PTGER1 (0.60) | PTGER1LMNACYP2C9KDM4ESMN1; SMN2 | |
| SCHEMBL5115968 | 0.85 | PTGER1 (0.61) | PTGER1LMNACYP2C9KDM4ESMN1; SMN2 | |
| SCHEMBL5126953 | 0.84 | PTGER1 (0.60) | PTGER1LMNAKDM4ESMN1; SMN2TBXA2R | |
| SCHEMBL5121292 | 0.84 | PTGER1 (0.60) | PTGER1LMNACYP2C9KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1874776-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | PTGER1 1/4885LMNA 2542/4885CYP2C9 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.